Chromatin topology reorganization and transcription repression by PML-RARα in acute promyeloid leukemia

Ping Wang1, Zhonghui Tang1,2, Byoungkoo Lee1, Jacqueline Jufen Zhu1,3, Liuyang Cai1, Przemyslaw Szalaj4, Simon Zhongyuan Tian1, Meizhen Zheng1, Dariusz Plewczynski4, Xiaolan Ruan1, Edison T. Liu1, Chia-Lin Wei1 and Yijun Ruan1,3*

*Correspondence: yijun.ruan@jax.org
1The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT 06030, USA
2Department of Genetics and Genome Sciences, University of Connecticut Health Center, 400 Farmington Avenue, Farmington, CT 06030, USA
Full list of author information is available at the end of the article

Abstract

Background: Acute promyeloid leukemia (APL) is characterized by the oncogenic fusion protein PML-RARα, a major etiological agent in APL. However, the molecular mechanisms underlying the role of PML-RARα in leukemogenesis remain largely unknown.

Results: Using an inducible system, we comprehensively analyze the 3D genome organization in myeloid cells and its reorganization after PML-RARα induction and perform additional analyses in patient-derived APL cells with native PML-RARα. We discover that PML-RARα mediates extensive chromatin interactions genome-wide. Globally, it redefines the chromatin topology of the myeloid genome toward a more condensed configuration in APL cells; locally, it intrudes RNAPII-associated interaction domains, interrupts myeloid-specific transcription factors binding at enhancers and super-enhancers, and leads to transcriptional repression of genes critical for myeloid differentiation and maturation.

Conclusions: Our results not only provide novel topological insights for the roles of PML-RARα in transforming myeloid cells into leukemia cells, but further uncover a topological framework of a molecular mechanism for oncogenic fusion proteins in cancers.

Keywords: PML-RARα, ChIA-PET, 3D genome architecture, CTCF, RNA polymerase II (RNAPII), Transcription factor (TF), Transcriptional regulation, Super-enhancer (SE)

Introduction

Leukemias are often triggered by chromosomal rearrangements, such as translocations and inversions, which can generate oncogenic fusion transcription factors [1, 2]. A hallmark in acute promyeloid leukemia (APL) is a chromosomal translocation that fuses the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptor alpha gene (RARα) on chromosome 17 into a fusion gene PML-RARα [3, 4]. This translocation, denoted as t(15;17)(q24;q21),
occurs in 98% of APL patients, and this fusion gene encodes a fusion protein PML-RARα, considered as a major etiological agent of APL. In normal myeloid cells, RARα (a nuclear receptor and transcription factor) plays important roles in myelopoiesis, especially in granulocytic and monocytic differentiation programs [5, 6]. However, the fusion protein PML-RARα in APL has been suggested to compete with endogenous RARα for binding at the same RA response elements (RAREs), which in turn leads to repression of normal RARα signaling in a dominant-negative manner [7]. It has also been hinted that PML-RARα could predominantly target promoters regulated by transcription factor PU.1 through protein-protein interactions between PU.1 and RAREh binding sites genome-wide [8]. Early studies have suggested that PML-RARα may also abnormally recruit a histone deacetylase (HDAC) and/or polycomb repressive complexes (PRCs) to target genes important in hematopoietic differentiation [9, 10], indicating that PML-RARα may have a role in altering chromosome configuration during APL genesis. Taken together, these investigations suggest a significant range of genome-wide restructuring induced by PML-RARα; however, how the comprehensive molecular mechanisms underlie the role of PML-RARα in leukemogenesis remains largely unknown.

Over the last decade, it has become clear that the human genomes are folded in complex 3-dimensional (3D) organizations in nuclei and that 3D chromatin architectures may be important in the higher-order regulation of transcription regulation [11]. Several studies have hinted that chromosomal rearrangements in acute myeloid leukemia (AML) with inv. (3)/t(3, 3) lead to long-range interactions characterized by the 3D repositioning of a GATA2 enhancer to the EVII promoter to ectopically activate EVII, which can cause dysregulation of both genes, with AML as the outcome [12, 13]. Another study has shown that the deletion of insulated chromatin domain boundaries could activate proto-oncogene expression through aberrant distal regulatory elements, thereby contributing to T cell acute lymphoblastic leukemia (T-ALL) [14]. Although these reports together indicated that chromatin configuration change might be an important feature in the transformation of normal cells into leukemic cells by oncogenic fusion proteins, specific evidence is lacking.

Considering that RARα binds directly to DNA genome-wide, we posit that the oncogenic fusion protein PML-RARα may also possess chromatin interaction properties, and alter the 3D genome topology as a critical event during leukemogenesis. To this end, we comprehensively analyzed normal myeloid cells with inducible PML-RARα, and patient-derived APL cells with native PML-RARα, to determine the roles of PML-RARα in 3D genome organization and transcription regulation, using integrative approaches including ChIA-PET for chromatin interactions, ChIP-seq for epigenomic states, and RNA-seq for transcriptional outputs. We discovered that PML-RARα mediated extensive long-range chromatin interactions genome-wide, distorted the established chromosomal folding topology in normal myeloid cells, and specifically repressed transcription of genes that are important to myeloid differentiation and maturation, together suggesting a topological mechanism for PML-RARα in leukemogenesis.
Results

Genome-wide chromatin interactions in normal myeloid cells and APL cells

To investigate the mechanisms through which PML-RARα leads to the development of promyelocytic leukemia phenotypes in myeloid cells, we employed a well-established PR9 cell line, which is derived from U937 myeloid precursors at the promonocytic stage. PR9 cell line possesses normal endogenous PML and RARα genes but also contains a transgenic construct inducible for PML-RARα expression via the addition of ZnSO4. Upon induction, the expression of PML-RARα in PR9 drives the cells to develop promyelocytic leukemia phenotypes [15]. It has also been shown that the protein expression level of PML-RARα in ZnSO4-treated PR9 cells is comparable to that in APL patient-derived NB4 cells [8]. Hence, by comparing PR9 cells under normal conditions (without PML-RARα protein) with PR9 cells under ZnSO4 induction conditions (with induced PML-RARα), we can investigate the dynamic changes of the myeloid genome mediated by the nascent fusion protein PML-RARα in PR9 cells (Fig. 1a).

To map the PML-RARα-initiated chromatin interactions to the myeloid genome, we performed ChIA-PET experiments using anti-PML and anti-RARα antibodies in both PR9 and PR9+Zn cells (Additional file 1: Table S1). Although the PR9 cells carry a transgenic PML-RARα construct, they would not express PML-RARα fusion protein without ZnSO4 induction and should retain the endogenous PML and RARα genes and normal expression of native PML and RARα proteins. After ZnSO4 treatment, hereafter referred to as PR9+Zn cells, the PR9+Zn cells should acquire the induced PML-RARα protein while still retaining the native PML and RARα proteins. Therefore, the PML- and RARα-enriched ChIA-PET experiments were expected to detect both of the native proteins and the induced PML-RARα in PR9+Zn cells, but only the native proteins in PR9 cells. As shown in the 2D chromatin contact profiles of the ChIA-PET data (Fig. 1b), the RARα ChIA-PET experiment generated distinctive and typical chromatin contact data that mapped along the 2D contact diagonal, whereas the PML ChIA-PET experiment produced no meaningful chromatin contact data. This was expected, as RARα is a DNA-binding transcription factor, and PML does not interact with chromatin in the nuclei. In contrast, we obtained extensive chromatin contact data in both the PML and RARα ChIA-PET experiments, from PR9+Zn cells (Fig. 1b). The striking similarity of chromatin contact patterns exhibited by these two ChIA-PET experiments in PR9+Zn cells using different antibodies (anti-PML and anti-RARα) validates that the induced fusion protein PML-RARα mediated new chromatin interactions in PR9+Zn cells.

To systematically investigate the impact of PML-RARα on the genomes, it is necessary to characterize the 3D genome organization in both normal myeloid cells and APL cells. Therefore, we first generated high-quality CCCTC-binding factor (CTCF)-enriched ChIA-PET data (Additional file 1: Table S1) and mapped the higher-order chromosomal folding architectures and the detailed chromatin domain topology mediated by CTCF in PR9 cells and PR9 cells with induced PML-RARα expression via the addition of ZnSO4. Overall, these two CTCF datasets were highly correlated (Additional file 2: Figure S1a-b), and the 2D contact profiles appeared to be identical (Fig. 1c), indicating that the ZnSO4 treatment did not directly alter the CTCF-mediated chromatin interactions in the myeloid genome.
Fig. 1 (See legend on next page.)
In addition, we also performed RNA polymerase II (RNAPII) ChIA-PET experiments (Additional file 1: Table S1) to map transcriptional chromatin interactions involving promoters and enhancers for active genes in PR9 and PR9+Zn cells. Globally, the two RNAPII ChIA-PET datasets appeared highly comparable (Fig. 1d and Additional file 1: Figure S1c-d); however, locally, we observed a significant difference (Fig. 1e). For example, at the locus of the gene CEBPB (encoding an important transcription factor for myeloid differentiation), it is observed that although the CTCF-mediated chromatin interactions in PR9 and PR9+Zn cells were very similar, the overwhelming chromatin contacts mediated by PML-RARα (detected by PML and RARα ChIA-PET data) in PR9+Zn cells appeared to overwrite the normal chromatin folding architecture predefined by CTCF around the CEBPB (Fig. 1e). Remarkably, the extensive RNAPII occupancy at the CEBPB promoter and the abundant looping contacts from the promoter to enhancers shown in PR9 cells (Fig. 1e, left) were abolished in PR9+Zn cells (Fig. 1e, right). Consequently, the transcription of CEBPB was repressed in PR9+Zn cells as measured by RNA-seq data. Together, these observations imply that PML-RARα could potentially have a strong impact on the chromatin folding architecture and transcription regulation in myeloid cells.

Topological reorganization of the myeloid genome by PML-RARα

To meticulously characterize the myeloid 3D genome organization and the impact of PML-RARα on myeloid genome topology, we first comprehensively characterized the CTCF ChIA-PET data in PR9 and PR9+Zn cells for their 3D chromatin organization, which reflected the native genome status of the myeloid genome. Because the two CTCF datasets were highly consistent (Fig. 1c) and that the ZnSO4 treatment in PR9 cells did not significantly change the CTCF chromatin interaction domains in the myeloid genome, we combined the two CTCF ChIA-PET datasets for increased data coverage to create a reference topological map mediated by CTCF of the myeloid genome in PR9 cells. Based on the connectivity of the CTCF loop clusters, we identified 2699 CTCF contact domains (CCDs) covering the majority of the myeloid genome (Fig. 2a),
Fig. 2 Reorganization of chromatin topology by PML-RARα-mediated chromatin interactions. a Chromatin domains and genomic coversages by CTCF (combined data in PR9 and PR9+Zn cells), RARα (PR9), and PML-RARα (combined data in PR9+Zn). The summary table shows domain numbers and size of interaction domains. CTCF data from B-lymphoblastoid cells (GM12878) was given as a reference. b Schematic of RARα and PML-RARα binding sites detected in PR9 and PR9+Zn cells detected by RARα and PML ChIA-PET experiments. RARα-specific (I), RARα and PML shared (II), and PML-RARα-specific binding sites were identified based on the combination patterns of the data in both PR9 and PR9+Zn cells. c Characterized RARα and PML-RARα binding sites in relation to TSS of genes. d Identification and classification of RARα and PML-RARα-associated chromatin interactions in PR9 and PR9+Zn cells. Three types of RARα and PML-RARα binding sites (b) involved in interactions are indicated as circles. The interactions between two sites are indicated with lines. The thickness of the lines corresponds to the number of interactions. Numbers of chromatin interactions in each category are given alongside the lines. e Screenshot of genome browser view of chromatin interaction loop, binding peak, and chromatin interaction domain for CTCF (green), RARα (blue), and PML-RARα (purple) at the ID1-HCK locus. Binding and looping signals for each protein factor were normalized. f Integrated 2D chromatin contact maps for the genomic segment (the same as in e) on chr20 for CTCF, RARα, and PML-RARα ChIA-PET data from PR9 and PR9+Zn cells. The red signals in the contact maps were from the combined CTCF and RARα data (left, PR9 cells) and the combined CTCF, RARα, and PML data (right, PR9+Zn cells). Light green and dark green triangles depict CTCF loop and CCD, respectively; light blue and dark blue triangles depict RARα loops and domains; light and dark purple depict PML-RARα loops and domains. Red triangles indicate RNAPII-mediated loops and domains. g 3D DNA-FISH validation. Two probes (red and blue) were designed at the corresponding position in the two separated CTCF domains as shown in e. Left panel: example 3D DNA-FISH images of separated and merged views for the two probes ("a" in red, "b" in green) were shown in both PR9 and PR9+Zn cells. Right panel: boxplot of spatial distance between the two probes measured microscopically from 300 nuclei in each of the PR9 and PR9+Zn cells. Mann-Whitney U test was used to test the difference. **p < 0.01. h 3D chromatin folding rendering. Simulated 3D models of average structure and ensemble cloud in PR9 (left) and PR9+Zn (middle) using the data in the corresponding region in f. Boxplot of the radial diameter of simulated 3D models. K-S test was used to test the differences. ***p < 2.2e−16.
which is comparable with the CCDs previously detected in the genome of B-lymphoblastoid GM12878 cells [16].

We then analyzed the RARα ChIA-PET and PML ChIA-PET data in PR9 and PR9+Zn cells. The analysis of the RARα ChIA-PET data in PR9 cells to detect endogenous RARα is straightforward, the same as we did for CTCF and RNAPII ChIA-PET data. However, in PR9+Zn cells, it is complicated, because both of the native RARα and the induced PML-RARα were expressed. Therefore, to distinguish the PML-RARα-associated chromatin contacts from the RARα-associated contacts, we dissected the ChIA-PET data (RARα) from PR9 cells and the data (PML and RARα) from PR9+Zn cells based on binding sites and chromatin loops. Hereby, we first analyzed the protein binding sites of the ChIA-PET data in both PR9 (with native RARα) and PR9+Zn cells (with native RARα and induced PML-RARα). To filter for high-confidence data, we defined a reliable binding site that was supported by at least two of the three independent ChIA-PET datasets (RARα data in PR9, RARα in PR9+Zn, and PML in PR9+Zn). Using this criterion, we identified 9458 RARα binding sites in PR9 cells and 8568 PML-RARα binding loci in PR9+Zn cells (Fig. 2b). The majority of the RARα binding sites (6748; 71%) were RARα-specific (detected in both PR9 and PR9+Zn cells, but not in PML data in PR9+Zn cells). However, there were 2710 (29%) RARα binding sites in PR9 cells that were also found in PML and RARα data in PR9+Zn cells, suggesting a possible co-occupancy or a competition mode at those loci by the native RARα and the induced PML-RARα. In addition, we identified 5858 PML-RARα-specific loci in PR9+Zn cells (Fig. 2b). Overall, both the native RARαs and fusion protein PML-RARαs demonstrated similar genome-wide chromatin binding capacity (9458 vs. 8568). Proportionally, 28% (1921/6748) of the RARα-specific binding sites were located proximal to the gene transcription start sites (TSS), whereas 41% (2405/5858) of the PML-RARα-specific binding sites and 55% (1483/2719) of PML-RARα sites co-localized with RARα sites were proximal to TSS (Fig. 2c). This observation suggests an increased tendency for PML-RARα to target gene promoters for the alteration of gene transcription regulation, in addition to binding at non-genic regions to impact chromatin architecture.

Next, we analyzed the chromatin contact loops mediated by RARα or PML-RARα, which identified 7223 high-confidence loops by RARα in PR9 cells, and 24,208 loops in PR9+Zn cells by combinatorial effects of native RARα and the induced nascent PML-RARα (Fig. 2d). Intriguingly, although the binding capacities of RARα and PML-RARα were similar (Fig. 2b), extensive chromatin interactions detected in PR9+Zn cells were largely associated with PML-RARα binding loci, particularly the PML-RARα-specific binding loci. Collectively, our observations imply a substantial impact from PML-RARα to alter the topological architecture of the myeloid genome.

To investigate how PML-RARα affects the myeloid genome, we aggregated the PML-RARα-associated chromatin interactions into PML-RARα contact domains, similarly to what we did for CTCF domains (Fig. 2a). Intriguingly, when integrating the PML-RARα complex domains into the CTCF-defined topological framework of the myeloid genome (Additional file 2: Figure S2a), we found that many (249) PML-RARα chromatin domains extended across the boundaries of two adjacent CCDs and connected parts of them, resembling “stitches” weaving multiple CCDs together. These “stitch” PML-RARα complex domains usually involved high levels of chromatin contacts.
(Additional file 2: Figure S2b) and were prevalently spread across the entire genome (Additional file 2: Figure S2c). The resulting “stitched CCD” by PML-RARα exhibited extended domain coverage (Additional file 2: Figure S2d), and thus potentially had a global impact on the overall topological organization of the myeloid genome. Such impacts were particularly visible at the level of topological domains. For example, at a 2.17-Mb segment of chr20, the two adjacent but separated CCD with scattered RARα binding and looping in PR9 cells were brought together by a PML-RARα chromatin domain with extensive binding and looping as shown in PR9+Zn cells (Fig. 2e, f). This observation was further validated by a two-color DNA-FISH experiment, showing that the two separated CTCF domains in PR9 cells were in much closer contacts in PR9+Zn cells than in PR9 cells (Fig. 2g). An ensemble structure-based algorithm was applied to the chromatin interaction data derived from PR9 and PR9+Zn cells (Additional file 3: supplementary methods) and elucidated the topological structural changes resulting from the action of the induced PML-RARα (Fig. 2h). Another example of the topological changes in PR9 cells before and after the ZnSO4 induction of PML-RARα was at a 3-Mb segment on chr18 (Additional file 2: Figure S2e-g). Taken together, our data demonstrated that the fusion oncoprotein PML-RARα acts through extensive chromatin binding and looping genome-wide and results in strong ectopic chromatin interactions that extend across the boundaries of CTCF-defined chromatin architectures in normal myeloid cells, thus leading to the topological reorganization of the myeloid genome into aberrant configurations in APL cells.

Alteration of gene expression by PML-RARα

Subsequently, we systematically analyzed the RNAPII ChIA-PET data in PR9 and PR9+Zn cells in relation to PML-RARα-defined chromatin domains and found that large numbers of RNAPII-associated chromatin interaction sites (proximal or distal to TSS) were co-occupied by PML-RARα in PR9+Zn cells (Additional file 2: Figure S3a), indicating that PML-RARα may also directly interfere with the transcription programs in myeloid cells. We then quantified RNAPII occupancy at these sites in PR9 cells before and after ZnSO4 induction of PML-RARα, to assess the effects of PML-RARα on RNAPII. While most of the loci showed insignificant changes after 4 h of ZnSO4 induction, we identified 871 (20%) loci that exhibited a significant reduction of RNAPII binding intensity (Fig. 3a). As analysis controls, less than 10% of the non-PML-RARα sites, including the RARα binding sites, showed changes in RNAPII occupancy, presumably due to systems noise. Therefore, our observation suggests that PML-RARα might specifically target a subset of RNAPII interaction loci and induce functions that repress gene transcription.

Next, we focused on the genes (n = 267) that were associated with the reduced RNAPII occupancy due to co-occupancy by PML-RARα and analyzed their transcription output using RNA-seq data over a time course during ZnSO4 induction of PML-RARα in PR9+Zn cells. Remarkably, more than half (n = 146) of these genes exhibited a corresponding pattern of transcriptional reduction over the time course during ZnSO4 treatment (Fig. 3b). To test if the observed transcriptional repression was directly related to the induction of PML-RARα, we added all-trans retinoic acid (ATRA) to PR9+Zn cells in order to rescue the gene expression potentially hampered by the induced PML-
Fig. 3 PML-RARα selectively disrupt RNAPII transcriptome. a Scatter plots showing signal reduction of RNAPII occupancy at PML-RARα binding sites (left), RARα binding sites (middle), and other loci (right) in PR9+Zn cells. The red dots represent the data points of RNAPII binding intensity which was significantly higher in PR9 than in PR9+Zn cells. The gray dots denote the RNAPII data points without significant changes in binding intensity between PR9 and PR9+Zn cells. The numbers of corresponding sites and the percentages of RNAPII changes are shown in each plot. b Expression profiles of representative genes (n = 267) whose promoters both exhibited decreased RNAPII binding intensity and overlapped with PML-RARα binding in PR9, PR9+Zn, and PR9+Zn+ATRA cells. The blue dashed box highlights the genes that were repressed by PML-RARα. The yellow dashed box highlights the genes (n = 119) that were repressed by PML-RARα but rescued by ATRA treatment. Key genes known to be involved in leukemia biogenesis are indicated. c Gene Ontology (GO) enrichment analysis of genes (n = 280) whose promoters represent decreased RNAPII binding intensity (control vs. treatment) in the PML-RARα category that were characterized in a. The x-axis denotes the enrichment score of −log10 (FDR). d Screenshot of browser views of chromatin interaction loops and peaks for RARα (blue), RNAPII (red), and PML-RARα (purple) at the IRF2BP2 locus in PR9 and PR9+Zn cells. Strand-specific RNA-seq data in PR9 and PR9+Zn cells with a time course of ATRA treatment. The IRF2BP2 region is highlighted. e Line plot shows the mean expression level of IRF2BP2 over the time points of ZnOS4 and ATRA treatments.
RARα. ATRA is an important drug in APL treatment. It causes degradation of the PML-RARα fusion protein through the ubiquitin-proteosome and caspase systems [17, 18]. We therefore performed a “rescuing” experiment by adding ATRA to the PR9 cells that were under ZnSO4 induction of PML-RARα. Remarkably, in the “rescuing” experiments, most of the genes (81.5%; 119/146) were recovered by ATRA treatment, showing increased transcription (Fig. 3b and Additional file 2: Figure S3b). Among these genes, many are known for their functions involved in myeloid cell differentiation, including transcription factors and cytokines, such as the previously reported CEBPB [19], ID2 [20], and SPI1 [21] involved in megakaryocytic and granulocytic differentiation. Gene Ontology analysis to this set of genes showed that they are significantly enriched in biological processes associated with hemopoiesis, immune processes, myeloid cell activation, and differentiation (Fig. 3c), further validating that at least part of the functions of PML-RARα is to act via repressing the transcription of genes involved in myeloid cell differentiation during APL pathogenesis.

As mentioned in Fig. 1e, the abundant RNAPII bindings and looping at the CEBPB promoter and its enhancer sites observed in PR9 cells were repressed by the induced PML-RARα in PR9+Zn cells while the CTCF-mediated chromatin folding structures unchanged, exemplifying a profound repressive function to transcription by PML-RARα. Similarly, at the IRF2BP2 locus, there was modest RARα ChIA-PET data and strong RNAPII-associated chromatin interactions between the IRF2BP2 promoter and multiple enhancers detected in PR9 cells. However, after induction by ZnSO4, robust PML-RARα binding peaks and chromatin loops appeared, which directly overlapped with the RARα and RNAPII associated chromatin sites as detected in PR9 cells. Coincidentally, the RNAPII signals were much reduced in PR9+Zn cells (Fig. 3d). Furthermore, the RNA-seq data in this region showed more than a 2-fold reduction of IRF2BP2 expression when PML-RARα was induced in PR9+Zn cells and, strikingly, rebounded after the addition of ATRA (Fig. 3d, e). Together, the high degree of correlation between the repression by ZnSO4 induction for PML-RARα expression and the liberation by ATRA treatment for PML-RARα degradation convincingly suggests that this set of genes may be the direct targets of PML-RARα for transcriptional repression in APL cells. It may also suggest mechanistically that PML-RARα forcefully compress the chromatin topological structure around myeloid-specific transcriptional cassette through its extensive chromatin binding and looping, and thus limit the access for transcription machinery.

Interference with transcription factor binding at enhancer sites by PML-RARα
We reasoned that the potential specificity of PML-RARα targeting a subset of actively transcribed genes in myeloid cells might be through interference with specific transcription factors (TFs). It is widely known that TFs can facilitate the physical chromatin contacts between promoters and distal regulatory elements by looping the intervening DNA between them [22, 23]. Specifically, PU.1 (also known as SPI1), known as a lymphoid-specific transcription activator, has been suggested to be associated with PML-RARα [8]. To identify specific TFs involved at the PML-RARα chromatin interaction sites, we performed TF motif analysis (Additional file 3: supplementary methods) and identified seven protein factors that were significantly enriched at PML-RARα
binding sites (Additional file 2: Figure S4a), including three TFs—PU.1, CEBPB, and IRF1 (Fig. 4a)—that are the most relevant and specific TFs in myeloid cells [8]. To further characterize these TFs, we performed ChIP-seq experiments and generated genome-wide binding profiles for PU.1, CEBPB, and IRF1 in PR9 and PR9+Zn cells, along with ChIP-seq of H3K9K14ac and P300 for promoters and enhancers. Interestingly, more than half of the TF binding sites found in PR9 cells were no longer present, or the binding signal intensities were significantly reduced, after PML-RARα induction in PR9+Zn cells (Fig. 4b). It is noteworthy that the binding profiles of these TFs were highly correlated with transcriptionally active marks H3K9K14ac and P300 for promoters and enhancers, and RNAPII-associated chromatin interactions, higher in PR9 control cells (PR9) but lower in the cells under ZnSO4 induction of PML-RARα (PR9+Zn). For example, at the PUL1 locus, PML-RARα bound specifically at the PU.1 promoter site and interacted with a number of enhancers as indicated by H3K9K14ac and P300 binding profiles. In particular, at the enhancer sites, the occupancy by the three TFs (PU.1, CEBPB, and IRF1) was notably abolished or reduced in intensity, whereas the binding peaks for H3K9K14ac and P300 at the enhancers were also either decreased in signal intensity or abolished (Fig. 4c, left). The same observations were also exemplified at the CEBPB (Fig. 4c, right) and IRF1 loci (Additional file 2: Figure S4b).

Taken together, our results indicate that PML-RARα directly interacts with specific chromatin loci and disrupts the transcription of specific TFs. More importantly, the reduced TF activities likely further dysregulate the transcription programs of downstream target genes that are important for normal myeloid cell differentiation.

**Disruption of super-enhancers by PML-RARα**

The experiments above showing that PML-RARα disrupts the cobinding of multiple cofactors at RARα sites suggest that PML-RARα would perturb the super-enhancer function. Super-enhancers (SEs), as a subset of regulatory elements, have been proposed to facilitate interactions between enhancers and promoters primarily associated with highly transcribed genes controlling cell identity and characteristically engaged multiple TFs at high intensity [24, 25]. Previous studies have shown that SEs are critical in establishing and maintaining cell-specific transcriptional regulation of gene expression as well as fine-tuning of the expression of many oncogenes [26, 27]. Given that the induced PML-RARα prominently targeted at genomic regions with high levels of H3K9K14ac modification (Fig. 5a), we used the H3K9K14ac ChIP-seq data to catalog SEs using the ROSE algorithm [26, 27] in PR9 and PR9+Zn cells (Fig. 5b). In total, we identified 521 SEs overlapped with PML-RARα binding sites in PR9+Zn cells (Additional file 2: Figure S5a), implying that PML-RARα may broadly interfere with the functions of SEs. Remarkably, of the 480 SEs identified in PR9 cells, more than half \( n = 247 \) lost their SE characteristics (H3K9K14ac signals) after Zn induction for PML-RARα PR9+Zn cells (Fig. 5c). It is observed that the RNAPII ChIA-PET data intensities (peaks and loops) associated with these SEs in PR9 cells were significantly decreased in PR9+Zn cells, in contrast to the induction of PML-RARα and associated binding peaks and loops in PR9+Zn cells (Fig. 5d).
Based on the connectivity of RNAPII ChIA-PET data, we detected 282 genes that were linked to the PML-RARα-affected SEs ($n = 247$). Subsequent GO analysis of this gene set identified 123 genes that were highly associated with functions in myeloid cell differentiation and positive regulation of myeloid leukocyte differentiation and myeloid cell homeostasis (Additional file 2: Figure S5b). Many of these 123 genes, including FOS, IRF2BP2, ID2, IRF1, IRF2BPL, and BHLHE40, were highly expressed in PR9 cells but repressed under ZnSO4 treatment conditions (Additional file 2: Figure S5c), as highlighted in Fig. 5b. In contrast, although 215 genes were found associated with the SEs ($n = 233$) that were not affected by PML-RARα, most of those genes were not associated with myeloid-specific functions (Additional file 2: Figure S5b).

At the IRF2BPL locus, only base-level RARα signals but substantial RNAPII peaks and loops connect the IRF2BPL promoter and enhancers in PR9 cells (Fig. 5e). However, following ZnSO4 induction, strong PML-RARα binding peaks and loops were observed in PR9+Zn cells overlapping directly with the RNAPII binding site loops...
Fig. 5  (See legend on next page.)
observed in PR9 cells. Consequently, the RNAPII signals in PR9+Zn cells were significantly diminished compared to the RNAPII signals in PR9 cells (Fig. 5e). Evidently, the H3K9K14ac peak profile in this region called for two SEs (Fig. 5f) interconnecting with the IRF2BPL promoter by a substantial number of RNAPII loops in PR9 cells. Notably, the SE signals were substantially reduced in PR9+Zn cells, presumably by the PML-RARα effects. Similarly, P300, another enhancer mark, showed the same pattern, with strong signals in PR9 cells, but diminished signals in PR9+Zn cells (Fig. 5f). Interestingly, the occupancy of IRF1 (a TF important for hematopoiesis) at the SE1 site was also much reduced in PR9+Zn cells. Correspondingly, the IRF2BPL expression was 2.5-fold downregulated in PR9+Zn cells (Fig. 5f). Another example is at the FOS locus (Additional file 2: Figure S5d).

Altogether, the above results demonstrated that PML-RARα may directly intrude super-enhancers, and the loss of properties of SEs may contribute to the disruption of RNAPII-mediated SE-to-promoter connectivity, consequently dysregulating gene transcription and altering the cell lineage controls during APL genesis.

Native PML-RARα in patient-derived APL cell functions similarly to the inducible PML-RARα

To validate the above findings in the PR9 cellular system, we analyzed NB4 cells, a cell line derived from an APL patient harboring the t(15,17) translocation and expressing a native PML-RARα fusion protein [28]. Therefore, the cellular state of NB4 (with native PML-RARα) would be comparable to PR9+Zn cells (with induced PML-RARα). We also treated NB4 cells with ATRA (NB4+ATRA) to deplete the native PML-RARα. These NB4+ATRA cells (with PML-RARα depleted) thus match with the PR9 cells (no PML-RARα). We reasoned that, with these parallels between the NB4 and the PR9 inducible systems, a comparative analysis of the two systems would yield insights into the property and function differences between the inducible and native PML-RARα (Fig. 6a). First, we performed RNA-seq for gene expression analysis in the pairs of NB4 vs. PR9+Zn cells and the NB4+ATRA vs. PR9 cells. The overall gene expression profiles between the two pairs exhibited high correlations (Fig. 6b and Additional file 2: Figure S5d).
S6a), indicating that the cellular systems of NB4 and PR9 were very comparable. However, when comparing the NB4 and NB4+ATRA cells, we observed that significant numbers of genes were upregulated, including many myeloid-specific genes (Additional file 2: Figure S6b). Specifically to the set of genes (n = 146) targeted by PML-
RARα (Fig. 3b), all of them were upregulated in NB4+ATRA cells (Fig. 6c), suggesting that native PML-RARα had similar effects to myeloid-specific genes as in the PR9 cellular system by the induced PML-RARα fusion protein.

Next, we performed ChIA-PET analyses for protein factors CTCF, PML-RARα, and RNAPII in NB4 cells and then compared with the same datasets derived from PR9+Zn (Fig. 6a; Fig. 1b–d). Similarly, the RNAPII and PML-RARα binding peak profiles between NB4 and PR9+Zn cells were also highly correlated (Additional file 2: Figure S6b). We further analyzed the chromatin contacts of the ChIA-PET data. The 2D contact profiles of the PML-RARα ChIA-PET data obtained in NB4 cells appeared to be very similar to the PML-RARα data in PR9+Zn cells, and obviously different from the RARα (no PML) data in PR9 cells (Fig. 6d), clearly indicating that the native PML-RARα in NB4 cells behaved similarly to the induced PML-RARα in PR9+Zn cells. As a reference, the CTCF-mediated chromatin contacts in NB4, PR9+Zn, and PR9 cells were highly comparable, as expected. More specifically, the CTCF loops and peaks were highly consistent in the three samples, and the PML-RARα loops and peaks were also consistent in NB4 and PR9+Zn cells, but not the same in PR9 cells, where there were no PML-RARα data except the data derived from RARα (Fig. 6e). Collectively, these observations suggested that the behavior of native PML-RARα in genome topological organization in NB4 cells was similar to that of the induced PML-RARα in PR9+Zn cells.

Furthermore, we observed that PML-RARα in NB4 cells also strongly inhibits RNAPII occupancy and transcriptional chromatin interactions at many myeloid-specific gene loci in PR9 cells (Additional file 2: Figure S6a). For instance, at the BHLHE40 locus in PR9 cells (Fig. 6f), RNAPII showed abundant occupancy at the gene promoter and mediated extensive chromatin loops to enhancers. However, at the same locus in PR9+Zn and NB4 cells, strong PML-RARα binding and looping were observed, and the RNAPII signals were diminished (Fig. 6f). To further investigate whether the native PML-RARα in NB4 cells affects the gene expression of myeloid-specific genes, as we showed in PR9 and PR9+Zn cells, we added ATRA to NB4 cells to deplete the native PML-RARα and then measured the transcripts by RNA-seq analysis. Differential expression analysis showed that many myeloid-specific genes expressed at high levels in PR9 cells (HCK, BHLHE40, CEBPB, IRF1, etc.) were repressed in NB4 cells and were reactivated after 24 h and 48 h of ATRA treatments (Additional file 2: Figure S6a). For example, the normal expression of BHLHE40 in PR9 cells was at a modest level (6.06 RPKM) and was repressed more than twofold (2.73 RPKM) after 4 h of ZnSO4 induction of PML-RARα in PR9+Zn cells. At the same locus in NB4 cells, BHLHE40 was repressed. However, after ATRA treatment, the expression of this gene increased more than tenfold (Fig. 6g). Another prominent example is at the FOS locus (Additional file 2: Figure S6c). Together, these results further suggested that our observations for PML-RARα in the PR9 inducible system faithfully reflected the native PML-RARα functions for chromosomal reorganization and transcriptional repression in patient-derived APL cells.

**Discussion**

In this study, we comprehensively mapped the 3D genome organizations and epigenomic features of normal myeloid cells and APL cells using integrative approaches
including ChIA-PET for chromatin topology, ChIP-seq for epigenomic state, and RNA-seq for transcriptional output, to analyze the effects of the oncogenic fusion protein PML-RARα on the myeloid genomes. Significantly, we employed an inducible myeloid system, in which the expression of the PML-RARα protein is precisely controlled by ZnSO4 induction. With this system, we investigated the dynamic changes in chromatin topology triggered by nascent PML-RARα in the initial transformation stage, beginning at the normal myeloid state in leukemogenesis. We also analyzed the patient-derived APL cells harboring native PML-RARα to validate our observations in the inducible myeloid system.

Collectively, in this study, we provided convincing data demonstrating that the PML-RARα proteins are aggressively involved in extensive chromatin interactions genomewide in a specific manner. Although the DNA-binding properties of PML-RARα are derived from RARα, more than two thirds (2/3) of the PML-RARα binding loci did not overlap with RARα binding sites, indicating that this fusion protein acquired novel chromatin interacting capacities. Intriguingly, our data indicated that PML-RARα did not directly interfere with CTCF binding and chromatin looping, but rather that many of the PML-RARα-mediated chromatin loops overlapped the boundaries of CTCF-defined topological structures, and acted as a “stitch” or “staple” to interconnect separate chromatin topological structures into much larger domains with more condensed configuration, thereby reshaping the chromatin topology in normal myeloid cells leading to leukemogenesis.

Importantly, we also demonstrated that PML-RARα specifically intrudes upon RNAPII-associated chromatin interaction domains of active genes in myeloid cells interrupting or competing for the binding of myeloid-specific TFs such as PU.1, IRF1, and CEBPB at enhancers and super-enhancers as demarcated by H3K9K14ac and P300 in open chromatin loci. The extensive chromatin binding and looping by PML-RARα could substantially compress the chromatin topological structures around myeloid-specific transcriptional cassettes, thus leading to transcriptional repression of genes that are critical for myeloid differentiation and maturation. Perturbation experiments via induction (by ZnSO4) and depletion (by ATRA) of in vivo PML-RARα in PR9 cells to repress and to rescue the normal myeloid differentiation expression cassette further validated the specificity of PML-RARα-targeted genes. Additional perturbation experiments with native PML-RARα in patient-derived NB4 cells by ATRA treatment provided further evidence verifying PML-RARα’s target specificity in gene transcription repression.

Taken together, our findings comprised a comprehensive view of the involvement of PML-RARα in chromatin topology during the early transformation process of PML-RARα-triggered APL genesis. Mechanistically, we posit that PML-RARα overrides the normal regulatory control of myeloid differentiation by reshaping the higher-order chromatin topology and compressing the transcriptional chromatin architectures. Therefore, the compressed chromatin domains would have reduced open access by specific TFs and RNAPII, thus repress the transcription of genes critical to myeloid differentiation, and ultimately lead to leukemogenesis. In sum, our results provide novel topological insights for the roles of PML-RARα in transforming myeloid cells into leukemia cells, likely a general mechanism for oncogenic fusion proteins in cancers.
Methods

Cell lines and culture conditions
PR9 (U937-PR9) cell line is a PML-RARα-inducible model constructed from U937, a normal myeloid precursor cell line without the t(15;17) translocation but expressing many myeloid-specific transcription factors important in myeloid development, including PU.1. To avoid the potential bias of clonal variations in culture, a single-cell subclone was selected. NB4 is a patient-derived APL cell line, carrying the t(15;17) translocation and expressing the PML-RARα fusion protein. Both PR9 and NB4 cells were cultured in RPMI 1640 (Thermo Fisher, A10491), supplemented with 10% fetal bovine serum (Thermo Fisher, 10082147). These cells were cultured at 37 °C, 5% CO₂, and ambient oxygen levels.

ZnSO₄ (Sigma, Z0251) was dissolved in sterile water as a stock solution at 100 mM. Induction for PML-RARα by ZnSO₄ in PR9 cells was 100 μM ZnSO₄ for 4 h.

ATRA (Sigma, R2625) was dissolved in ethanol as a stock solution at 1 mM. ATRA treatment in NB4 cells was 10⁻⁶ M ATRA for 24 or 48 h.

ChIA-PET library preparation
ChIA-PET libraries with an antibody against PML, RARα, RNAPII, and CTCF were constructed using about 10⁸ input cells from PR9, PR9+Zn, and NB4 cell cultures, following the ChIA-PET protocol [29, 30]. The ChIA-PET libraries were sequenced by paired-end reads using Illumina instruments.

ChIP-seq
In this study, we generated ChIP-seq data from PR9 and PR9+Zn cells for TFs of P300, PU.1, CEBPB, and IRF1, using the following antibodies: anti-P300 (Abcam, ab14984), anti-PU.1 (Santa Cruz, sc-352X), anti-IRF1 antibody (Santa Cruz, sc-497x), and anti-CEBPB antibody (Santa Cruz, sc-150x), and followed standard ChIP-seq protocol [8].

RNA isolation and RNA-seq library preparation
Total RNA was extracted with RNeasy mini kit (Qiagen, 74106) from the following cells: PR9 cells, PR9 cells treated with ZnSO₄ (final concentration is 100 μM) at different time points (4 h, 6 h, 12 h, 24 h), PR9 cells pre-incubated with ZnSO₄ for 4 h and then treated with ATRA (final concentration is 1 μM) for another 24 or 48 h, and NB4 cells and NB4 cells treated with ATRA (final concentration is 1 μM) for 24 and 48 h. Prior to RNA-seq library preparations, rRNAs were depleted using Ribo-Zero rRNA removal kits (Illumina Inc., MRZH11124) from total RNA. Then, RNA libraries were prepared by the ScriptSeq RNA-seq library preparation kit (Illumina Inc., SSV21124). The RNA-seq libraries were sequenced using the NextSeq 500 platform for paired-end sequencing.

3D DNA-FISH
The 3D DNA-FISH was performed with custom-synthesized oligonucleotides probes (MYcroarray) according to candidate genome loci (probe A—chr20: 31,261,904-31,361,904; probe B—chr20: 30,141,728-30,241,728) [16]. PR9 cells and PR9 cells treated with ZnSO₄ (final concentration is 100 μM) for 4 h were spun down onto a coverslip slide.
coating with poly-lysine for 20 min; then, the slides were washed with PBS for 3 times and air-dried. The cells were fixed in methanol/acetic acid solution (3:1) for 5 min at 4°C, air-dried, and washed with PBS for 5 min. The cells were dehydred through an ethanol series (70%, 90%, 100%) and air-drying. Then, the cells were permeabilized with 0.5% Triton X-100 in PBS on ice for 5 min and washed with PBS for 5 min. Customized FISH probe (MYcroarray) was warmed and mixed with hybridization buffer well. The cells and the probe mix were simultaneously subjected to DNA denaturation at 80°C for 5 min. The hybridization was performed at 37°C in the humid dark chamber overnight. After coverslip removal, one wash for 10 min at RT with 2×SSC/50% deionized formamide, pH 7.0, followed by one wash for 10 min at RT with 2×SSC and two washes for 10 min at 55°C with 0.2×SSC were performed. Then, cells on the slides were incubated with ProLong™ Gold Antifade Mountant with DAPI (Thermo Fisher, 36931) in PBS buffer for 5 min and examined under the Leica SP8 confocal microscope. The distances between the probe pair were measure in 3D with IMARIS 9 software.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13059-020-02030-2.

Additional file 1: Supplementary tables. Table S1. Dataset used in this study. Table S2. Reagents used in this study. Table S3. Software and algorithms used in this study.

Additional file 2: Supplementary figures. Figure S1. Comparison of CTCF and RNAPII binding and looping in PR9 and PR9+Zn cells. Figure S2. PML-RARα-mediated chromatin interaction domain and impacts on the myeloid genome. Figure S3. Transcription repression of myeloid specific genes by PML-RARα. Figure S4. Further details of motif analysis around PML-RARα binding sites. Figure S5. Super-enhancers of myeloid specific genes affected by PML-RARα. Figure S6. Additional examples of PML-RARα in NB4 cell.

Additional file 3: Supplementary methods. 1. ChIA-PET data processing and clustering of interaction PETs. 2. Comparison of ChIA-PET data for calling of binding peaks, loops, and chromatin domains. 3. Identification and classification of RARα and PML-RARα binding sites. 4. Identification and characterization of PML-RARα-mediated chromatin interactions. 5. Visualization of 2D contact map and BASiC browser. 6. 3D chromatin structure modeling, measurement of 3D structure condensation and visualization. 7. Identification of binding motifs at PML-RARα peak regions. 8. Comparison of RNAPII-mediated chromatin interactions between control and treatment condition. 9. RNA-Seq and differential gene expression analysis. 10. ChiP-Seq analysis. 11. Identification and characterization of super-enhancers. 12. Quantification and statistical analysis methods.

Additional file 4: Table S4. Differential expression of genes (267) affected by PML-RARα in PR9 cells.

Additional file 5. Review history.

Acknowledgements
The authors thank Dr. Oscar Junhong Luo and Dr. Guliang Li for the initial data analysis and Dr. Roel Verhaak for the valuable comments on the manuscript.

Peer review information
Yixin Yao was the primary editor of this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Review history
The review history is available as Additional file 5.

Authors’ contributions
YR conceptualized and supervised this study. PW designed the experiments and generated all genomic data with the assistance from XR and MZ on library construction. ZT, BL, and SZT analyzed the data. JJZ and LC performed the 3D DNA-FISH experiments and data analysis. PS and DP performed the simulation and visualization of the 3D chromatin folding models. PW, ZT, and YR interpreted the results and wrote the manuscript with inputs from ETL and C-LW. The authors read and approved the final manuscript.

Funding
YR is supported by NIH UM1 (HG009409, ENCODE), US4 (DK107967, 4DN), HFSP (RGP0039/2017), and the Roux family endowment. ETL is supported by NCI grant P30CA034196. PW is supported by the Young Scientists Fund of the National Natural Science Foundation of China (Grant No: 31100942). DP and PS are also supported by the Polish National Science Centre (2014/15/B/ST6/05082; UMO-2013/09/B/NZ2/00121), National Leading Research Centre in Białystok, and European Union under the European Social Fund.
Availability of data and materials

Genome-wide sequencing raw reads and processed files have been deposited at GEO. The accession number for the ChIA-PET, ChIP-seq, and RNA-seq datasets for PR9 and NB4 cells reported in this paper is GEO: GSE137662 [31]. H3K9K14ac ChIP-seq data of PR9 cells were downloaded from the GEO database under the accession number of GSM468215. All datasets, materials, and softwares used in this study are listed in Additional file 1 Table S1, S2, and S3, respectively.

Ethics approval and consent to participate

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT 06030, USA. 2Present Address: Sun Yat-sen University, Guangzhou, Guangdong, China. 3Department of Genetics and Genome Sciences, University of Connecticut Health Center, 400 Farmington Avenue, Farmington, CT 06030, USA. 4Centre of New Technologies, University of Warsaw, Stefana Banacha 2c, 02-097 Warsaw, Poland.

Received: 26 February 2020 Accepted: 27 April 2020

Published online: 11 May 2020

References

1. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7:233–50.
2. Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer. 2001;1:245–50.
3. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science. 1991;254:1371–4.
4. de The H, Chomienne C, Lanotte M, Degas L, Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347:558–61.
5. Apfel CM, Kamber M, Klaus M, Mohr P, Keidel S, LeMotte PK. Enhancement ofHL-60 differentiation by a new class of retinoids with selective activity on retinoid X receptor. J Biol Chem. 1995;270:30765–72.
6. Botting J, Castro DS, Öberg F, Nilsson K, Perlmann T. Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation. J Biol Chem. 1997;272:9443–9.
7. Pandolfi PP. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet. 2001;10:769–75.
8. Wang K, Wang P, Shi J, Zhu X, He M, Jia X, et al. PML-RARalpha targets promoter regions containing PU.1 consensus by PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74:423–36.
9. Martens JHA, Birnkran AB, Simmer F, Francoijs K-J, Nebbioso A, Ferrara F, et al. PML-RARalpha/RXR alters the epigenetic topology for transcription. Proc Natl Acad Sci U S A. 2009;106:20222–7.
10. Villa R, Pasini D, Guiterrez A, Morey L, Occhionorelli M, Viré E, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell. 2007;11:513–25.
11. van Steensel B, Furlong EEM. The role of transcription in shaping the spatial organization of the genome. Nat Rev Mol Cell Biol. 2019;20:327–37.
12. Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369–81.
13. Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Brenrick EH, Engel JD, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25:415–27.
14. Hinz D, Weintraub AS, Day DS, Walton A-L, Bak RO, Li CH, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 2016;351:1454–8.
15. Grignani F, Ferrucci PF, Testa U, Falcioli M, Alcalay M, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74:423–31.
16. Zhang T, Luo OJ, Li X, Zheng M, Zhu JJ, Szalaj P, et al. CTCF-mediated human 3D genome architecture reveals chromatin topology for transcription. Cell. 2015;163:1611–27.
17. Yang X-W, Wang P, Liu J-Q, Zhang H, Xi W-D, Jia X-H, et al. Coordinated regulation of the immunoproteasome subunits by PML-RARalpha and PU.1 in acute promyelocytic leukemia. Oncogene. 2014;33:2700–8.
18. Zheng P-Z, Wang K-K, Zhang G-Y, Huang Q-H, Du Y-Z, Zhang Q-H, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci. 2005;102:7653–8.
19. Duprez E, Wagner K, Koch H, Tenen DG. CBFBbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J. 2003;22:5806–16.
20. Nigten J, Breems-de Ridder MC, Erpelnick-Verschueren CAJ, Nikoloski G, van der Reijden BA, van Wageningen S, et al. ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells. Leukemia. 2005;19:899–805.
21. Muller BU. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood. 2006;107:3330–8.
22. Nolis IK, McKay DJ, Mantouvalou E, Lomvardas S, Merika M, Thanos D. Transcription factors mediate long-range enhancer-promoter interactions. Proc Natl Acad Sci U S A. 2009;106:20222–7.
23. Zlotorynski E. Gene expression: the yin and yang of enhancer-promoter interactions. Nat Rev Mol Cell Biol. 2018;19:75.
24. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155:934–47.
25. Pott S, Lieb JD. What are super-enhancers? Nat Genet. 2015;47:8–12.
26. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320–34.
27. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307–19.
28. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15; 17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080–6.
29. Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P, et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell. 2012;148:84–98.
30. Li X, Luo OJ, Wang P, Zheng M, Wang D, Piecuch E, et al. Long-read ChIA-PET for base-pair-resolution mapping of haplotype-specific chromatin interactions. Nat Protoc. 2017;12:889–915.
31. Wang P, Tang ZH, Lee B, Zhu JF, Cai LY, Szlaj P, Tian ZY, Zheng MZ, Plewczynski D, Ruan X, Liu ET, Wei CL, Ruan YJ. Chromatin topology reorganization and transcription repression by PML-RARα in acute promyeloid leukemia. Datasets Gene Expression Omnibus. 2019. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137662. Accessed 5 Dec 2019.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.